BofA analyst Jason Gerberry raised the firm’s price target on Oculis (OCS) to $32 from $31 and keeps a Buy rating on the shares. Q4 financials featured cash burn in line with expectations and no major pipeline updates, notes the analyst, who adjusted the firm’s price target to account for the latest financing. The firm thinks that the company’s ophthalmology portfolio is underappreciated relative to peak sales, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target lowered to $29 from $30 at H.C. Wainwright
- Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions
- Oculis Holding AG Reports 2024 Financial Results
- Oculis Holding’s Promising Ophthalmology Portfolio and Financial Stability Lead to Buy Rating
- Oculis Holding AG Reports 2024 Financial Results and Clinical Progress